bluebird bio (BLUE) PT Slashed to $8 at RBC Capital, Citing Three Severe Adverse Events
Tweet Send to a Friend
RBC Capital analyst Luca Issi lowered the price target on bluebird bio (NASDAQ: BLUE) to $8.00 (from $80.00) while maintaining ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
